Targeted Investigational Oncology Agents in the NCI-60: A Phenotypic Systems-based Resource

Area of Science:

• Oncology
• Pharmacology
• Bioinformatics

Background:

• The NCI-60 human tumor cell line panel is a key resource for cancer drug discovery.
• Compound screening data from NCI-60 aids in understanding drug mechanisms of action.
• Signature sensitivity/resistance patterns serve as fingerprints for chemotherapeutic agents.

Purpose of the Study:

• Establish a new, publicly accessible NCI-60 data resource.
• Include screening data for a large set of approved and investigational oncology agents.
• Provide tools for comparative analysis of drug screening data.

Main Methods:

• Screening of 175 FDA-approved oncology drugs (AOD) and over 825 investigational oncology agents (IOA) against the NCI-60 cell line panel.
• Data collection encompassing diverse therapeutic targets and mechanisms (>250).
• Development of visualization and analysis tools for the NCI-60 resource.

Main Results:

• A comprehensive dataset of NCI-60 screening results for AOD and IOA is now publicly available.
• The resource covers a wide array of therapeutic agents and targets.
• Integrated tools facilitate comparative studies of individual and multiple compounds.

Conclusions:

• The new NCI-60 resource enhances cancer research by providing extensive drug screening data.
• This platform supports the identification of novel chemotherapeutics and understanding of drug action.
• Public access to this data accelerates the discovery of new oncology treatments.